Clinical data and diagnostic findings of the study groups
| Characteristics/diagnostics | Double-blind doxycycline | Double-blind control | Observational doxycycline | Observational control |
|---|---|---|---|---|
| Female/male | 2/5 | 3/2 | 24/31 | 11/22 |
| Median (IQR) | Median (IQR) | Median (IQR) | Median (IQR) | |
| Age at onset (years) | 58.0 (56.0–66.0) | 72.0 (55.0–73.0) | 62.1 (57.3–69.9) | 65.0 (56.0–68.0) |
| Days from onset to start of (placebo) therapy | 95 (75–145) | 152 (99–701) | 138 (92–212) | − |
| Days of doxycycline/placebo therapy | 61 (11–156) | 34 (1–439) | 88 (48–148) | − |
| MMSE points | 21 (21–25) | 16 (8–25) | 20 (12–24) | 12 (0–21) |
| Barthel index | 45 (20–70) | 50 (20–65) | 65 (20–95) | 20 (0–50) |
| Codon 129% (n) | ||||
| M/M | 0 (0) | 20 (1) | 25 (14) | 24 (8) |
| M/V | 43 (3) | 40 (2) | 40 (22) | 39 (13) |
| V/V | 57 (4) | 40 (2) | 35 (19) | 36 (12) |
| τ Protein | 2955 (1059–7984) | 2400 (1200–8093) | 3320 (1095–5968) | 4700 (2943–10 805) |
| Neuron-specific enolase | 107 (25–204) | 73 (49–97) | 30 (21–41) | 61 (36–120) |
| Positive cases | Per cent | Per cent | Per cent | Per cent |
| 14-3-3 positive | 94 | 92 | 78 | 95 |
| PSWCs in EEG | 13 | 42 | 15 | 21 |
| CJD-typical MRI | 83 | 92 | 89 | 75 |
| Hyperintensities of basal ganglia | 79 | 75 | 81 | 70 |
| Hyperintensities cortical | 31 | 53 | 31 | 53 |
CJD, Creutzfeldt-Jakob disease; MMSE, Mini-Mental State Examination.